These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2294653)

  • 1. Cerebral muscarinic receptors in primary degenerative dementia as evaluated by SPECT with iodine-123-labeled QNB.
    Weinberger DR; Mann U; Gibson RE; Coppola R; Jones DW; Braun AR; Berman KF; Sunderland T; Reba RC; Chase TN
    Adv Neurol; 1990; 51():147-50. PubMed ID: 2294653
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo imaging of cerebral muscarinic receptors with I-123 QNB and SPECT: studies in normal subjects and patients with dementia.
    Weinberger DR; Jones DW; Sunderland T; Lee KS; Sexton R; Gorey J; Reba R
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():194A-195A. PubMed ID: 1498808
    [No Abstract]   [Full Text] [Related]  

  • 3. Muscarinic acetylcholine receptors in Alzheimer's disease. In vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography.
    Holman BL; Gibson RE; Hill TC; Eckelman WC; Albert M; Reba RC
    JAMA; 1985 Dec; 254(21):3063-6. PubMed ID: 3877181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic cholinergic receptor binding: in vivo depiction using single photon emission computed tomography and radioiodinated quinuclidinyl benzilate.
    Drayer B; Jaszczak R; Coleman E; Storni A; Greer K; Petry N; Lischko M; Flanagan S
    J Comput Assist Tomogr; 1982 Jun; 6(3):536-43. PubMed ID: 6980235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in muscarinic receptor binding in limbic areas of Alzheimer brain.
    Rinne JO; Rinne JK; Laakso K; Paljärvi L; Rinne UK
    J Neurol Neurosurg Psychiatry; 1984 Jun; 47(6):651-2. PubMed ID: 6736999
    [No Abstract]   [Full Text] [Related]  

  • 6. Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease.
    Brown D; Chisholm JA; Owens J; Pimlott S; Patterson J; Wyper D
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):296-300. PubMed ID: 12552349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia.
    Weinberger DR; Jones D; Reba RC; Mann U; Coppola R; Gibson R; Gorey J; Braun A; Chase TN
    J Neuropsychiatry Clin Neurosci; 1992; 4(3):239-48. PubMed ID: 1498576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinergic muscarinic receptors in rat myocardium: properties of [3H]quinuclidinyl benzilate [QNB] binding sites.
    Mittal CK
    Indian J Exp Biol; 1985 Jun; 23(6):300-5. PubMed ID: 4077129
    [No Abstract]   [Full Text] [Related]  

  • 9. Regional covariance of muscarinic acetylcholine receptors in Alzheimer's disease using (R, R) [(123)I]-QNB SPECT.
    Colloby SJ; McKeith IG; Wyper DJ; O'Brien JT; Taylor JP
    J Neurol; 2015 Sep; 262(9):2144-53. PubMed ID: 26122542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoradiographic evidence that (R)-3-quinuclidinyl (S)-4-fluoromethylbenzilate ((R,S)-FMeQNB) displays in vivo selectivity for the muscarinic m2 subtype.
    Boulay SF; Sood VK; Rayeq MR; Zeeberg BR; Eckelman WC
    Nucl Med Biol; 1996 Oct; 23(7):889-96. PubMed ID: 8971856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease.
    Wyper DJ; Brown D; Patterson J; Owens J; Hunter R; Teasdale E; McCulloch J
    Eur J Nucl Med; 1993 May; 20(5):379-86. PubMed ID: 8519256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT.
    Pakrasi S; Colloby SJ; Firbank MJ; Perry EK; Wyper DJ; Owens J; McKeith IG; Williams ED; O'Brien JT
    J Neurol; 2007 Jul; 254(7):907-13. PubMed ID: 17361343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating suppressing factor for the muscarinic acetylcholine receptor in patients with senile dementia of the Alzheimer type.
    Kitano S; Morimoto S; Fukuo K; Miya K; Yasuda O; Koh E; Hirotani A; Nakahashi T; Tamatani M; Ogihara T
    Gerontology; 1992; 38 Suppl 1():24-8. PubMed ID: 1459469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concerning the distribution of cerebral muscarinic acetylcholine receptors in Alzheimer's disease.
    Zeeberg B
    Arch Neurol; 1991 Nov; 48(11):1117-8. PubMed ID: 1953390
    [No Abstract]   [Full Text] [Related]  

  • 15. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
    Luthin GR; Wolfe BB
    Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.
    Luthin GR; Wolfe BB
    J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type.
    Nordberg A; Alafuzoff I; Winblad B
    Neurosci Lett; 1986 Sep; 70(1):160-4. PubMed ID: 3774212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of lithium on [3H](-)quinuclidinyl benzilate [( 3H](-)QNB) binding to rat brain muscarinic cholinergic receptors.
    Hruska RE; Ludmer LM; Pert A; Bunney WE
    J Neurosci Res; 1984; 11(2):171-7. PubMed ID: 6423831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
    Watson M; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potency ratio for the inhibition of 3H-QNB and 3H-cis-methyldioxolane binding predicts agonist or antagonist activity on muscarinic receptors.
    Moret C; Pastrie I; Briley M
    Methods Find Exp Clin Pharmacol; 1988 Oct; 10(10):619-21. PubMed ID: 3236936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.